These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 7986719

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate.
    Hampton KK, Preston FE, Lowe GD, Walker ID, Sampson B.
    Br J Haematol; 1993 Jun; 84(2):279-84. PubMed ID: 8398831
    [Abstract] [Full Text] [Related]

  • 3. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate.
    Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Bottasso B, Simoni L, Rosenberg RD.
    Blood; 1990 Dec 15; 76(12):2540-5. PubMed ID: 2265248
    [Abstract] [Full Text] [Related]

  • 4. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
    Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Santagostino E, Tradati FC, Rosenberg RD.
    Br J Haematol; 1991 Dec 15; 79(4):606-11. PubMed ID: 1772782
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC.
    Philippou H, Adami A, Lane DA, MacGregor IR, Tuddenham EG, Lowe GD, Rumley A, Ludlam CA.
    Thromb Haemost; 1996 Jul 15; 76(1):23-8. PubMed ID: 8819246
    [Abstract] [Full Text] [Related]

  • 7. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
    Goudemand J, Peynet J, Chambost H, Négrier C, Briquel ME, Claeyssens S, Derlon-Borel A, Guérois C, Caron C, Scherrmann JM, Debray M, Bridey F.
    Thromb Haemost; 1998 Dec 15; 80(6):919-24. PubMed ID: 9869161
    [Abstract] [Full Text] [Related]

  • 8. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates.
    Kim HC, McMillan CW, White GC, Bergman GE, Horton MW, Saidi P.
    Blood; 1992 Feb 01; 79(3):568-75. PubMed ID: 1531035
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of high purity factor IX concentrates and a prothrombin complex concentrate in a canine model of thrombogenicity.
    MacGregor IR, Ferguson JM, McLaughlin LF, Burnouf T, Prowse CV.
    Thromb Haemost; 1991 Nov 01; 66(5):609-13. PubMed ID: 1803625
    [Abstract] [Full Text] [Related]

  • 11. Biochemical and in vivo properties of high purity factor IX concentrates.
    Berntorp E, Björkman S, Carlsson M, Lethagen S, Nilsson IM.
    Thromb Haemost; 1993 Nov 15; 70(5):768-73. PubMed ID: 8128433
    [Abstract] [Full Text] [Related]

  • 12. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.
    White GC, Shapiro AD, Kurczynski EM, Kim HC, Bergman GE.
    Thromb Haemost; 1995 May 15; 73(5):779-84. PubMed ID: 7482403
    [Abstract] [Full Text] [Related]

  • 13. Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: An in vitro evaluation.
    Brinkman HJ, Patiwael S, Tripathi S, Meijers JC.
    Thromb Res; 2016 Mar 15; 139():102-10. PubMed ID: 26916304
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
    Aznar JA, Cabrera N, Matysiak M, Zawilska K, Gercheva L, Antonov A, Montañés M, Páez AM, Lissitchkov T.
    Haemophilia; 2009 Nov 15; 15(6):1243-8. PubMed ID: 19659601
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group.
    Poon MC, Aledort LM, Anderle K, Kunschak M, Morfini M.
    Transfusion; 1995 Apr 15; 35(4):319-23. PubMed ID: 7701550
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
    Négrier C, Menart C, Attali O, Petit PY, Lienhart A, Dechavanne M, Ingerslev J.
    Blood Coagul Fibrinolysis; 1998 Mar 15; 9 Suppl 1():S135-41. PubMed ID: 9819045
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics, thrombogenicity and safety of a double-treated prothrombin complex concentrate.
    Morfini M, Longo G, Berntorp E, Cinotti S, Filimberti E, Messori A, Nilsson IM, Rossi Ferrini P.
    Thromb Res; 1993 Aug 01; 71(3):175-84. PubMed ID: 8211885
    [Abstract] [Full Text] [Related]

  • 19. Monoclonal antibody-purified factor IX--comparative thrombogenicity to prothrombin complex concentrate.
    Kim HC, Matts L, Eisele J, Czachur M, Saidi P.
    Semin Hematol; 1991 Jul 01; 28(3 Suppl 6):15-9. PubMed ID: 1780766
    [No Abstract] [Full Text] [Related]

  • 20. Factor IX from prothrombin complex concentrate augments low dose tissue factor-triggered thrombin generation in vitro.
    Hasan S, Abuelkasem E, Williams B, Henderson R, Mazzeffi MA, Tanaka KA.
    Br J Anaesth; 2018 Oct 01; 121(4):936-943. PubMed ID: 30236256
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.